Table 3.
Asthma Medication Use at entry into the Adolescent Master Protocol (AMP), by HIV status. Within the HIV-infected group, asthma medication use is shown overall and by type of antiviral regimen.
| HIV-Infected | HEU1 | ||||
|---|---|---|---|---|---|
| Asthma Medication | RTV2 (N=41) |
Other PI (N=16) |
Not on PI (N=32) |
Overall (N=89) |
(N=39) |
| Bronchodilators | 36 (88%) | 16 (100%) | 32 (100%) | 84 (94%) | 38 (97%) |
| Controller Medications | 17 (41%) | 12 (75%) | 19 (59%) | 48 (54%) | 20 (51%) |
| Inhaled Fluticasone | 2 (5%) | 3 (19%) | 3 (9%) | 8 (9%) | 7 (18%) |
| Other Inhaled Corticosteroid3 | 3 (7%) | 2 (13%) | 2 (6%) | 7 (8%) | 1 (3%) |
| Montelukast | 7 (17%) | 5 (31%) | 10 (31%) | 22 (25%) | 5 (13%) |
| Fluticasone + Montelukast | 0 (0%) | 1 (6%) | 3 (9%) | 4 (4%) | 4 (10%) |
| Other inhaled steroid + Montelukast | 5 (12%) | 1 (6%) | 1 (3%) | 7 (8%) | 3 (8%) |
1
HEU: HIV-exposed, uninfected
2
RTV: Ritonavir
3
Includes beclomethasone, budesonide, mometasone, triamcinalone